Billed as nonaddictive, new pain pill could soon win FDA approval. Questions remain about whether the non-opioid drug developed by Vertex Pharmaceuticals could be effective for chronic pain.

NEW YORK (AP) - Stocks that traded heavily or had substantial price changes Tuesday: Vertex Pharmaceuticals Inc., down $14.44 to $217.33. The drug developer reported disappointing fourth quarter ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...

WASHINGTON (AP) — Federal ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998. Sold by Vertex Pharmaceuticals in 50-milligram tablets ...

CAMBRIDGE, Mass. (AP) — The Food and Drug Administration is attaching a black box warning to the Vertex Pharmaceuticals hepatitis C treatment Incivek over a potentially fatal rash. The FDA says ...

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

One-year data suggest allogeneic stem cell-derived islet-cell therapy could become a future option for those with type 1 ...